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Original article 
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Abstract 
Background: Specific single nucleotide polymorphisms (SNPs) near the 
interferon lambda 3 (IFN3) gene (formal interleukin 28B), influence the response 
to treatment with interferon in hepatitis C patients. We aimed to investigate such 
an influence in hepatitis D patients. 
Methods: Study population consisted of hepatitis D patients who were previously 
treated with pegylated interferon for one year and spontaneous clearers of the 
virus post recent superinfection. SNP of IFN3, rs12979860 was determined by 
PCR-RFLP protocol. 
Results: The total number of patients were 64; median age 30.5 years, male 53. 
Patients with sustained virologic response one year post-treatment were 17, non-
responders 29, relapsers 11, and spontaneous clearers post superinfection 07. 
Cirrhosis was present in 28 (44%). IFN3, rs12979860 genotype CC was present in 
41 (64.1%), CT 21 (32.8%), and TT 02 (3.1%). There was no difference in the body 
mass index, baseline ALT, HBeAg and HBV DNA status among patients with 
sustained response and response failure (no response or relapse). The median 
age of response failures was 33.5 years compared to 26 in responders (p=0.024). 
They had higher GGT levels (p=0.030) and cirrhosis (0.003). Genotype CC was 
present in 29/40 of response failures compared to 9/17 of the responders 
(p=0.152). Logistic regression analysis showed that cirrhosis was the 
independent risk factor for failure to have a response (p=0.001). 4/7 patients with 
spontaneous clearance had genotype CC. 
Conclusions: IFN3 rs12979860 SNP does not have any significant influence on 
the long term hepatitis D clearance. Presence of cirrhosis may influence the 
response. 
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Introduction 
Genome-wide association studies (GWAS) studies have shown that a single nucleotide polymorphism 
(SNP) rs12979860 near the interferon lambda-3 (IFN3) gene, (formally known as interleukin 28B), on 
chromosome 19, is associated with variable responses to the interferon therapy in hepatitis C. The CC 
genotype of IFN3 rs12979860 is associated with two to three fold increases in sustained virologic 
response as compared with either CT or TT genotype [1,2]. In case of hepatitis B, the association of IFN-
3 polymorphism with response to interferon has not been confirmed [3]. A recent study has shown that 
IL28-B polymorphisms are related to differing response to pegylated interferon (Peg-IFN) in the treatment 
of HBeAg-negative chronic hepatitis B, which may also be hepatitis B virus genotype dependent [4]. 
Although the prevalence of hepatitis D has decreased in Europe, it is still prevalent in many 
countries of Asia Pacific region including Pakistan [5–7]. Hepatitis D is a difficult-to-treat infection. 
Interferon, standard or pegylated, is the only treatment option available to hepatitis D patients. Peg-IFN 
for hepatitis D is of limited efficacy [8,9] and the addition of a nucleoside analog does not improve the 
response [10]. The agent seems effective in suppressing viral and liver disease activity in some patients, 
but this improvement is not sustained in the majority of patients. 
Not enough data is available on the association between IFN3 polymorphisms and hepatitis D 
virus (HDV) response to Peg-IFN based therapy and spontaneous clearance rate. This study aimed to 
find out IFN3 rs12979860 genotypes in responders, non-responders and relapsers to the Peg-IFN 
therapy and in spontaneous clearers of hepatitis D infection. 
Methods 
Patients 
Study population consisted of HBsAg and anti-HDV antibody positive patients with compensated liver 
disease who visited our clinic in a period of two years for whom longitudinal observations were available 
from the medical records. Patients were considered to have chronic hepatitis D when HDV-RNA was 
detectable in patients reactive for anti-HDV antibodies for more than six months. Subjects were 
considered to have achieved spontaneous viral clearance post superinfection if they had two consecutive 
negative HDV-RNA results six months apart without any antiviral treatment. Patients with detectable HDV 
RNA who had been previously treated with Peg-IFN for one year, were categorized as responders, non-
responders and relapsers to the therapy. Responders were defined as patients who had negative HDV 
RNA at the end of treatment and one year post treatment. 
Informed consent was taken from each patient. Baseline characteristics at the time of 
commencement of therapy were noted from the records, including age, sex, body mass index (BMI), 
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HBeAg status, HBV DNA and HDV RNA, qualitative or quantitative, and type and duration of therapy 
received. 
Exclusion criteria were treatment with standard interferon, duration of treatment less than or more 
than one year, concomitant or previous nucleos (t) ide consumption, co-infection with hepatitis C or HIV, 
decompensated cirrhosis, alcohol abuse, autoimmune disorders or hepatocellular carcinoma. We also 
excluded patients where end of treatment and follow up HDV RNA status was not documented. The study 
was approved by the Ethics Committee of the hospital. 
Blood samples were taken for HDV RNA and SNP. SNP of IFN3 rs12979860 was determined by 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) protocol as mentioned 
below. HDV RNA clearance was compared in lambda-3 rs12979860 “CC” with “non CC”. 
IL28B genotyping 
7 mL of blood will be drawn into EDTA (lavender top) tube. Genotyping for the IL-28B rs12979860 C/T 
polymorphism was performed by polymerase chain reaction based restriction fragment length 
polymorphism assay. Genomic DNA was extracted from whole blood samples by means of the QIAamp 
DNA blood mini kit (Qiagen, Milan, Italy) according to manufacturer’s instruction. A 242 base pair (bp) 
product was obtained with the forward primer 5-GCTTATCGCATACGGCTAGG-3 and the reverse 
primer 5-AGGCTCAGGGTCAATCACAG-3, previously described [11]. PCR amplification was carried out 
in a total volume of 10 l containing 10 mM Tris–HCl (pH 8.3), 50 mM KCl, Tween-20 0.01%, 0.2 mM 
deoxyribonucleotides, 2–4 pmol of each primer, 2.0 mM MgCl2, 0.5 units hot-start Taq DNA polymerase 
(Promega). Samples containing 10 ng of genomic DNA were subjected to 40 cycles of denaturation (at 95 
°C for 30 s), annealing (at 62 °C for 30 s), and elongation (at 72 °C for 30 s) using a Perkin Elmer 9700 
thermal cycler. In a total volume of 20 l, 10 l of the amplified products were digested with 1 unit of the 
BstU-I restriction endonuclease (New England Bioloabs, UK) at 60 °C overnight. The fragments digested 
were, respectively, 135 + 82 + 25 bp for the C allele and 160 + 82 bp for the T allele variant. The 
fragments were resolved by electrophoresis in 3.5% agarose gel after staining with ethidium bromide. In 5 
patients the genomic region encompassing the IL-28B rs12979860 C/T polymorphism was sequenced 
with results confirming those obtained by the RFLP assay. 
HBV DNA 
Serum HBV-DNA levels were quantified with the Real Time PCR COBAS AmpliPrep/COBAS TaqMan 
HBV Test 2.0 (Roche Molecular Systems, NJ, USA). HBsAg, HBeAg, anti-HBs, anti-HBe were detected 
by the Elecsys instrumental platform (Roche Diagnostics, Italy). 
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HDV RNA extraction 
Viral RNA was extracted from 600µl of the sample (serum) using an automated procedure (Qiasymphony, 
QIAGEN, Hilden, Germany). The manufacturer’s protocol was followed, and the purified RNA was eluted 
in 60µl of RNase-free water. 
Reverse transcription 
The reverse transcription reaction (RT) was performed using first strand M-MLV reverse transcriptase kit 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Briefly, 5µl out of the 
extracted RNA was added to 15 µl of RT mixture containing RT buffer, dNTP mix (10 mM each of four 
deoxynucleoside triphosphate stocks), 50 µM random hexamer primer and 75 U of M-MLV reverse 
transcriptase. The RT reaction mixture was incubated at 37
◦
C for 120 min, and then at 85 °C for 5 min to 
inactivate the enzyme. The resulting 20 µl of cDNA was kept at 20°C until use. 
Statistical analyses 
Statistical analyses were performed using SPSS, release 20 (IBM Corporation, Chicago, IL, USA). 
Categorical variables were expressed as frequencies (%) while continuous variables were presented as 
mean ± standard deviation or median with 25
th
-75
th
 percentiles inter-quartile range (IQR). Differences 
between categorical variables were assessed by means of chi-square or Fisher’s exact test, while those 
between continuous variables were evaluated using the Mann-Whitney U test. Multivariate logistic 
regression analysis with the stepwise forward selection was performed with p-values of less than 0.05 as 
the criteria for model inclusion. For this model, continuous variables were expressed as dichotomous 
using median values. 
Results 
The total number of patients were 64; mean age 31.8±10.1 years, median 30.5 (range 13-55 and 
interquartile range 23.2-40.0), male 53, median body mass index (BMI) 22.6 (IQR: 20.1-27.7), alanine 
aminotransferase (ALT) 80 (IQR: 51-118), gamma glutamyl transferase (GGT) 55 (IQR: 30-100). Patients 
with sustained virologic response were 17, non-responders, relapsers 11, and spontaneous clearers post 
recent superinfection 07. Cirrhosis of the liver as evident from histology, ultrasound or clinical examination 
was present in 28 (44%) and two patient was diabetic. IFN3, rs12979860 genotype CC was present in 
41 (64.1%), CT 21 (32.8%), and TT 02 (3.1%). 
There was no difference in the age, BMI, baseline ALT, HBeAg and HBV DNA status among 
patients with sustained response one year post-treatment and response failures (no response and 
relapse) to the treatment (Table 1). The median age of response failures was 33.5 (IQR: 25.7-42.7) years 
compared to 26 (IQR: 21.0-33.5) in responders (p=0.024). They had higher GGT levels (p=0.030) and 
cirrhosis (0.003). Genotype CC was present in 16/28 patients who showed end of treatment virologic 
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response (ETR) compared to 22/29 who could not achieve ETR (p=0.134). These figures were 9/17 for 
sustained responders versus 29/40 for response failures (0.152) (Figure 1). IFN3, rs12979860 SNP was 
not associated with any clinical parameter (cirrhosis, ALT and GTT levels). Regression analysis showed 
that cirrhosis was the independent risk factor for failure to have a sustained response at one year of post 
treatment follow up (p=0.001). 4/7 patients with spontaneous clearance had genotype CC. 
Discussion 
We could not find any beneficial effects of favorable IFN3 genotype CC on treatment response in 
hepatitis D in spite of substantial evidence reported with hepatitis C. Two recently published papers have 
discussed the role of IFN3 polymorphism in hepatitis D [12,13]. However, any association of this 
polymorphism with treatment response still remains in debate. The mechanism by which interferon 
lambda3 genotypes regulates the antiviral response to the interferon alpha remains unclear. Unlike type I 
interferons, the target cell populations of interferon-lambda is restricted and mainly include epithelial cells 
and hepatocytes [14]. Like interferon alpha, interferon lambda upregulates interferon stimulated genes 
(ISGs) by inducing JAK-STAT Pathway. However, interferon lambda binds to a different receptors than 
interferon alpha [15,16]. Guedj J, et al showed that after initiation of Peg-IFN therapy, a median delay of 9 
days was observed with no significant changes in HDV level. Thereafter, HDV declined in a biphasic 
manner, where a rapid first phase lasting for 25 days was followed by a slower or a plateau second 
phase. None of the patients with flat second phase in HDV achieved complete viral clearance. The 
interferon lambda-3 polymorphism (rs12979860) was not associated with kinetic parameters [17]. 
Genetic analysis of the host may predict which patients are more likely to respond to treatment. 
IFN3 genotypes are only one of many factors that might influence the response to Peg-IFN and should 
be interpreted in the context of other clinical factors. Other factors that play a role in modulating response 
to the Peg-IFN therapy, may include HDV and HBV genotypes, viral loads, and baseline liver fibrosis. In 
our country hepatitis D genotype 1 is prevalent [18] and hepatitis B genotype D is present in more than 
90% cases [19]. These genotypes are less responsive to treatment to treatment with interferon. There 
might be a role of IFN3 CC genotype in influencing response to Peg-IFN therapy in hepatitis B genotype 
D patients [4]. However, it is apparent from our study that even having a favorable IFN3 CC 
polymorphism was not helpful in our hepatitis D patients (figure 1). 
Our patients who cleared the virus in response to treatment were younger, had lower GGT levels 
and were not having clinical cirrhosis. It has been shown previously that age at the time of diagnosis and 
the presence of cirrhosis are associated with disease progression in hepatitis D [20]. One way of 
interpreting our data may be that as the degree of fibrosis in liver progresses with time, the chances of 
clearing virus become less. 
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This study has some limitations of our study. The study included patients who were treated 
retrospectively. There may be a selection bias as polymorphism was checked in patients who visited the 
clinic during the study period, not all treated patients as we did not have preserved samples and took 
samples as they visited us. The number of patients were small. However, sample size is bigger than other 
two recent studies [12,13], and we included patients treated with Peg-IFN only, not the standard 
interferon. Though the study relied on the baseline laboratory results done in the past, the tests were 
done in a single center. Baseline quantitative PCR and HBsAg levels, and early virological response at 
week 12 were not available in all patients so these variables could not be analyzed. 
Spontaneous clearance of both viruses is seen in patients with HBV and HDV confection, but 
seven patients with spontaneous clearance in our study were HBsAg positive even before HDV exposure 
suggesting that these patients most likely had superinfection and then cleared the virus as documented 
from their records. The number is small to draw any conclusion and the natural comparator group for 
spontaneous clearers in a larger study would be all those patients who did not clear the virus 
spontaneously. The long-term follow-up studies indicate that several patients defined as responders after 
a follow-up of six months relapse in the long run [21]. We defined responders who had undetectable HDV 
RNA one year after stopping the treatment. There is a possibility that some of the responders would have 
become relapsers if had followed up for a longer duration. The study cohort does not include any patient 
who had cleared HBsAg as well. The lack of effect of rs12979860 SNP would not rule out other the role of 
other SNPs which need to be addressed in future studies. 
In conclusion, IFN3 rs12979860 SNPs in patients infected with HDV does not have any 
significant influence on the long term virologic clearance. The degree of fibrosis may influence the 
response to the Peg-IFN therapy. 
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Figure 1. IFN3 rs12979860, CC or non-CC genotypes, and response to pegylated interferon in patients 
with hepatitis D. 
ETR: end of treatment virological response; VR-1: virological response persisting one year post-treatment. 
 
Table 1: Characteristics of patients who received pegylated interferon therapy 
 Responders 
N=17 
Non-responders and 
relapsers 
n=40 
P value 
Gender 
male 
female 
 
14 (82%) 
03 
 
34 (85%) 
06 
 
 
1.00 
Age 
mean±S.D. 
Median (IQR) 
 
27.2±7.6 
26 (21.0-33.5) 
 
34.0±10.6 
33.5 (25.2-42.7) 
 
 
0.024* 
Body mass index (kg/m
2
) 
mean±S.D, 
median (IQR) 
 
24.0±4.7 
23.2 (20.1-28.3) 
 
23.7±5.6 
22.5 (20.0-27.0) 
 
 
0.711 
Cirrhosis 2 22 0.003* 
Alanine aminotransferase (IU/L) 
mean±S.D. 
median (IQR) 
 
147±180 
87 (56.5-137.5) 
 
103±78 
94 (49-118) 
 
 
0.545 
Gamma glutamyl transferase (IU/L) 
mean±S.D. 
median (IQR) 
 
51±39 
36 (30.0-64.5) 
 
103±97 
80.5 (31.7-132.2) 
 
 
0.030* 
HBeAg reactive 4 (24%) 16 (40%) 0.364 
HBV DNA detected 3 (18%) 14 (35%) 0.224 
Interferon 3 type 
CC 
non-CC 
 
9 (53%) 
8 
 
29 (73%) 
11 
 
 
0.152 
P values by Fisher exact test or Man-Whitney U test. *statistically significant p values S.D.: standard deviation; IQR: 
interquartile range 

